Literature DB >> 3729331

In vitro susceptibility of Brucella melitensis to new cephalosporins crossing the blood-brain barrier.

E Palenque, J R Otero, A R Noriega.   

Abstract

The in vitro susceptibilities of 83 clinical isolates of Brucella melitensis to seven cephalosporins and a monobactam were determined. Ceftizoxime, ceftriaxone, and cefotaxime were the most effective agents tested, with MICs ranging from 0.25 to 2 micrograms/ml. Moxalactam, cefoperazone, cefuroxime, and ceftazidime showed MICs between 4 and 64 micrograms/ml, with moxalactam being the most active agent in this group. Aztreonam showed poor activity, with MICs higher than 64 micrograms/ml.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3729331      PMCID： PMC180392          DOI： 10.1128/AAC.29.1.182

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Protean manifestations of nervous system brucellosis. Case histories of a wide variety of clinical forms.

Authors:  R W FINCHAM; A L SAHS; R J JOYNT
Journal:  JAMA       Date:  1963-04-27       Impact factor: 56.272

2.  Determination of the in vitro sensitivity of Brucella strains to rifampicin.

Authors:  M J Corbel
Journal:  Br Vet J       Date:  1976 May-Jun

Review 3.  The new beta-lactamase-stable cephalosporins.

Authors:  H C Neu
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

4.  Antibiotic therapy of bacterial meningitis: lessons we've learned.

Authors:  M A Sande
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

5.  In vitro susceptibility of Brucella to various antibiotics.

Authors:  W H Hall; R E Manion
Journal:  Appl Microbiol       Date:  1970-10

6.  Comparison of ceftriaxone and traditional therapy of bacterial meningitis.

Authors:  B L Congeni
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  Treatment of bacterial meningitis with ceftizoxime.

Authors:  G D Overturf; D C Cable; D N Forthal; C Shikuma
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

8.  In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole.

Authors:  A Gutiérrez Altés; M Díez Enciso; P Peña García; A Campos Bueno
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

Review 9.  Pharmacokinetic profile of ceftriaxone in man.

Authors:  I H Patel; S A Kaplan
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

Review 10.  Human brucellosis.

Authors:  E J Young
Journal:  Rev Infect Dis       Date:  1983 Sep-Oct
  10 in total
  4 in total

Review 1.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

2.  In vitro activities of ceftriaxone and fusidic acid against 13 isolates of Coxiella burnetii, determined using the shell vial assay.

Authors:  H Torres; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

3.  Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.

Authors:  J Ariza; J Bosch; F Gudiol; J Liñares; P F Viladrich; R Martín
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

4.  Efficacy evaluation of some antibiotics against syrian brucella spp isolates, in vitro.

Authors:  Mazen Safi; Ayman Al-Mariri
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.